权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Validation of Biomarkers of Risk for the Early Detection of Lung Cancer

肺癌早期检测风险生物标志物的验证

基本信息

批准号：
9463350
负责人：
PIERRE P. MASSION
金额：
$ 71.13万
依托单位：
VANDERBILT UNIVERSITY MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-08-16 至 2021-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9463350
关键词：
Address Area Assessment tool Autoantibodies Benign Biodistribution Biological Biological Markers Blood Bronchoscopy Caliber Cancer Etiology Cessation of life Characteristics Clinical Clinical Data Collaborations Communities Computer software Country Data Set Development Diagnosis Diagnostic Disease Dose Early Detection Research Network Early Diagnosis Evaluation Funding Glutamates Goals Human Image Imaging Device Imaging technology Individual Institution Investigation Label Lead Lung nodule Malignant - descriptor Malignant neoplasm of lung Measurement Measures MicroRNAs Military Personnel Modeling Molecular Molecular Profiling National Cancer Institute Nested Case-Control Study Nodule Observational Study Oxidative Stress Paper Patient Care Patient Recruitments Patients Phase Population Positron-Emission Tomography Prospective Studies Prospective cohort Prospective cohort study Pulmonary Mass RNA Research Research Design Resources Risk Risk Assessment Screening for cancer Specimen Sputum System Testing Time Tissues Tracer Urine Validation Work biobank biomarker development biomarker evaluation biomarker validation bronchial epithelium cancer biomarkers candidate marker chest computed tomography clinical decision-making clinical predictors cohort complement C4d computed tomography screening design diagnostic accuracy diagnostic biomarker disorder risk early detection biomarkers high risk imaging biomarker imaging probe improved in vivo industry partner interdisciplinary approach lung cancer screening molecular imaging molecular marker multidisciplinary novel predictive modeling programs prospective public health relevance rate of change recruit screening standard of care tool tumor tumor DNA validation studies

项目摘要

DESCRIPTION (provided by applicant): This multidisciplinary effort of experts in biomarker research proposes to renew their commitment to the EDRN and to lead our Clinical Validation Center ever closer to impacting patient care. Therefore we propose to test best candidate biomarkers of lung cancer developed at our and other institutions for added value in the assessment of the risk for, and diagnosis of, lung cancer compared to the standard of care. The hypothesis is that addition of imaging and molecular biomarkers measured by chest computed tomography and in the sputum, the bronchial epithelium and blood, likely in a multivariable manner, could improve the identification of high risk individuals for lung cancer and improve CT screening overall results by reducing false-positive tests. We propose a three way approach. First we will test candidate biomarkers for lung cancer development in an observational study of selected very high risk individuals from the Nashville community performing repeated measurements of clinical, imaging (low-dose chest CT) variables, as well as molecular biomarker signatures, some of which will be obtained from bronchoscopy. Second, we propose to validate the most promising diagnostic candidate signatures to each test in carefully designed prospective study of individuals presenting with indeterminate pulmonary nodules. Third, we will test a novel molecular imaging tracer in a population of intermediate and high risk lung nodules. This tracer will be compared to standard of care FDG PET, and if significantly better, should have huge impact on the management of lung nodules. Our CVC will also centralize an effort to collect and store pertinent clinical data and tissues (blood, urine, and the airways specimens) and make these resources available to the community and to collaborators within and outside of the EDRN program, including the industry partners.